exemestane,tamoxifen,triptorelin
azurity pharmaceuticals,astrazeneca,pfizer
['soft trial']
at #asco23 results of a pam50-based risk of recurrence score analysis from the #soft trial (n=1066): pam50 ror scores are prognostic (but not predictive of ofs benefit) in premenopausal women very young women (&lt;40yrs) were enriched of more aggressive forms of bc (more lumb) 
MD, Medical Oncologist🇮🇹•Research Fellow at @JulesBordet Institute in Brussels🇧🇪 Great interest in #BreastCancer and #ImmunoOncology